ClinicalTrials.govrestricted
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
ClinicalTrials.gov study NCT05495724. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4